These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26394624)

  • 1. Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.
    Breyer J; Gierth M; Shalekenov S; Aziz A; Schäfer J; Burger M; Denzinger S; Hofstädter F; Giedl C; Otto W
    World J Urol; 2016 May; 34(5):709-16. PubMed ID: 26394624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
    Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
    Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
    Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer.
    Zhao J; Dong D; Sun L; Zhang G; Sun L
    Int Braz J Urol; 2014; 40(2):179-89. PubMed ID: 24856504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.
    Byrne RR; Shariat SF; Brown R; Kattan MW; Morton RA JR; Wheeler TM; Lerner SP
    J Urol; 2001 May; 165(5):1473-9. PubMed ID: 11342899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
    March-Villalba JA; Ramos-Soler D; Soriano-Sarrió P; Hervás-Marín D; Martínez-García L; Martínez-Jabaloyas JM
    Urol Oncol; 2019 Feb; 37(2):158-165. PubMed ID: 30446453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Krüppel-like factor 4 is a novel prognostic predictor for urothelial carcinoma of bladder and it regulates TWIST1-mediated epithelial-mesenchymal transition.
    Tseng WC; Chuang CW; Yang MH; Pan CC; Tarng DC
    Urol Oncol; 2016 Nov; 34(11):485.e15-485.e24. PubMed ID: 27519276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial-To-Mesenchymal Transition and Its Correlation With Clinicopathologic Features in Patients With Urothelial Carcinoma of the Bladder.
    Singh R; Ansari JA; Maurya N; Mandhani A; Agrawal V; Garg M
    Clin Genitourin Cancer; 2017 Apr; 15(2):e187-e197. PubMed ID: 27601277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin.
    Raspollini MR; Luque RJ; Menendez CL; Bollito E; Brunelli M; Martignoni G; Montironi R; Cheng L; Blanca A; Baroni G; Minervini A; Lopez-Beltran A
    Hum Pathol; 2016 Nov; 57():78-84. PubMed ID: 27473264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A; Kausch I; Feller AC; Krüger S
    Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence.
    Ziaran S; Harsanyi S; Bevizova K; Varchulova Novakova Z; Trebaticky B; Bujdak P; Galbavy S; Danisovic L
    Eur J Histochem; 2020 Mar; 64(2):. PubMed ID: 32214283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
    Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
    J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection.
    Liu B; Miyake H; Nishikawa M; Fujisawa M
    Urol Oncol; 2015 Mar; 33(3):110.e11-8. PubMed ID: 25262382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma.
    Rao J; Seligson D; Visapaa H; Horvath S; Eeva M; Michel K; Pantuck A; Belldegrun A; Palotie A
    Cancer; 2002 Sep; 95(6):1247-57. PubMed ID: 12216092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
    Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
    J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study.
    Santi R; Cai T; Nobili S; Galli IC; Amorosi A; Comperat E; Nesi G
    Virchows Arch; 2018 Apr; 472(4):605-613. PubMed ID: 29525824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies.
    Bryan RT; Atherfold PA; Yeo Y; Jones LJ; Harrison RF; Wallace DM; Jankowski JA
    J Pathol; 2008 Jun; 215(2):184-94. PubMed ID: 18393367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.